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OUTCOMES RESEARCH - A CLINICIAN'S PERSPECTIVE
Henry R. Black, M.D., Department of Preventive Medicine,
Rush-Presbyterian St. Luke's Medical Center, Chicago, IL.
Outcomes research (OR) proposes to study the appropriateness
of health care services in order to identify the manner by which
diseases can be most effectively prevented, diagnosed and
treated. Proponents of OR claim that this methodology will do
this better than the randomized clinical trial (RCT), which we
have traditionally used as the gold standard to obtain answers
to many of the same questions. OR, like RCTs, uses the tools
of epidemiology and biostatistics but OR studies the factors
involved in the process of care in existing large data bases, not
in specifically recruited and highly selected cohorts. Contrary to
what some critics of RCTs have said, both methods try to
understand what is responsible for better clinical outcomes but
OR concentrates more on patient satisfaction and the cost-
effective use of health care resources. RCTs, which have been
called "efficacy" studies, have actually provided us with
considerable data on outcomes and much valuable guidance for
therapy. These efficacy studies, however, have been widely
criticized for not reflecting the "real world" of medical care and
for creating artificial outcomes which can not replicated in the
usual clinical setting. This presentation will review clinical trial
methodology, discuss RCTs which are designed to be
"effectiveness" studies (large simple trials) and compare to
RCTs to OR. I will suggest that unless OR finds a way to
control bias and identify the innumerable confounders that can
effect the therapeutic process, it will not be able to accomplish
its goals.
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CELLULAR RESPONSES TO MECHANICAL STRESS
Peter F. Davies, Department of Pathology and Medicine,
Pritzker School of Medicine, University of Chicago
Virtuallyall cells accommodateor respond to the mechanical
environment. The responses of endothelium to externally-
generated forces such as those associated with blood flow is
a useful paradigm for mechanical stress mechanisms in cells
in general. In the case of the endothelium there are important
physiological and pathological cardiovascular consequences
related to endothelial biomechanical properties. I will review
the concepts of flow-mediated mechanotransduction in
endothelium, particularly studies conducted in vitro. The
concept of intrinsic cell tension and its modification by an
external load will be considered within the realm of direct
displacement of a mechanical sensing system in
endothelium. This will be contrasted with the generation of
flow-mediated responses by changes in the local
concentrations of potent chemicals at the cell membrane, an
indirect mechanism of flow signalling that mayor may not
require coordinate effects of direct forces acting on the cell,
such as shear stress. State-of-the-art techniques to measure
the surface features of endothelial cells as they pertain to the
distribution of flow forces will be presented.
AJH-APRIL 1995-VOL.8, NO.4, PART2
Friday, 5/19, Mercury Ballroom, 5:00 pm-7:00 pm
Theme I: Endothelial and Physical Factors in
Hypertension
ENDOTHELIAL FACTORS IN THE CARDIO-
VASCULAR SYSTEM
T.F. Luscher. Cardiology, Cardiovascular Research,
University Hospital/lnselspital, Bern, Switzerland
The cardiovascular system is regulated by neuronal
influences, circulating hormones as well as paracrine and
autocrine mechanisms in the blood vessel wall. Endothelial
factors playa primary role by releasing substances which
can regulate vascular tone and structure as well as adhesion
of circulating blood cells. Prostacyclin (PGIz) activates
cAMP and is a vasodilator and platelet inhibitor function.
Nitric oxide (NO) formed from L-arginine via the activity of
endothelial NO synthase (eNOS). Platelets also express
eNOS. eNOS is increased in its expression by shear stress
and estrogen and possibly other factors. The L-arginine
nitric oxide pathway also is stimulated by shear stress as
well as receptor-operated mechanisms (i.e. acetylcholine,
histamine, bradykinin, substance P, ATP/ADP and
thrombin). NO acts as a vasodilator and platelet inhibitor via
cGMP. Furthermore, endothelial cells produce constricting
factors such as endothelin-I (ET I), thromboxane Az and
prostaglandin Hz. ETI activates ETA- and ETg-receptors on
vascular smooth muscle to cause contraction and endothelial
E'Ijj-receptors cause vasodilation (by NO and PGlz). In
vascular smooth muscle cells, NO is an inhibitor and ETI a
stimulator of migration and proliferation.
The endothelium is a target and mediator of cardiovascular
disease and may exhibit profound dysfunction as
cardiovascular disease progresses.
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ENDOTHELIUM-DERIVED VASOACTIVE FACTORS IN
HYPERTENSION
P.M. Vanhoutte,I.R.I.S., Courbevoie,France
The endothelium plays a pivotal role in a number of responses
(relaxations or contractions) of isolatedarteriesand veins from animals
and humans. The endothelium-dependent relaxations are due to the
release hy the endothelial cells of potent nonprostanoid vasodilator
substances. Among these, the bestcharacterized is endothelium-derived
relaxing factor (EDRF) which most likely is nitric oxide (NO). Nitric
oxide is formed by the metabolism of I-arginine by the enzyme NO
synthase in the endothelial cells. In arterial smooth muscle, the
relaxationsevokedby EDRF are explained bestby the stimulation by
NO of solubleguanylate cyclase that leads to theaccumulationof cyclic
GMP. In a numberof animalblood vessels. the endothelialcells release
a substance that causes hyperpolarization of the cell membrane
(endothelium-derived hyperpolarizing factor, EDHF). In blood vessels
from hypertensiveanimals,endothelium-dependent relaxation usually
arereduced. A decreased release of EDRF and/or a reducedsensitivity
of vascularsmoothmuscle to NO can contribute to the reduction. The
limited information available on isolated human blood vessels, or
obtained in situ in human limbs, concur with the conclusions reached
with isolated animal tissues. In addition to relaxing factors, the
endothelial cells can produce contracting substances (endothelium-
derivedcontractingfactors; EDCFs) which include superoxideanions,
endoperoxide, thromboxaneAZ and the potent vasoconstrictorpeptide
endothelin. To judge from animal studies, the propensity to release
EDCFsis maintained or evenaugmented in diseased blood vessels. This
is particularly the case in arteries taken from spontaneously
hypertensive animals. where the release of endothelium-derived
endoperoxide(s) is increased. andthe sensitivity of the vascularsmooth
muscle to the EDCF is augmented. The switch from a normally
predominant release ofEDRF to that of EDCFs may playa crucial role
in the vascularhyperreactivity seen in hypertension.
